PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 7181945-1 1982 The pharmacological response to vitamin K1 (Konakion) in anticoagulated (prothrombin complex activity less than 30%) New Zealand white rabbits was determined by measuring prothrombin complex activity (P.C.A.) Vitamin K 1 32-42 prothrombin Oryctolagus cuniculus 73-84 7181945-1 1982 The pharmacological response to vitamin K1 (Konakion) in anticoagulated (prothrombin complex activity less than 30%) New Zealand white rabbits was determined by measuring prothrombin complex activity (P.C.A.) Vitamin K 1 32-42 prothrombin Oryctolagus cuniculus 171-182 183212-1 1976 The ability of confluent monolayers of H-35 cells, originally obtained from a rat hepatoma, to synthesize prothrombin in response to vitamin K1 (phylloquinone) was studied. Vitamin K 1 133-143 coagulation factor II Rattus norvegicus 106-117 183212-1 1976 The ability of confluent monolayers of H-35 cells, originally obtained from a rat hepatoma, to synthesize prothrombin in response to vitamin K1 (phylloquinone) was studied. Vitamin K 1 145-158 coagulation factor II Rattus norvegicus 106-117 4524646-4 1974 A 3.5-A resolution difference Fourier map obtained for the gamma-hydroxy derivative of the vitamin K(1)-Fab" complex shows that this hapten is bound in a shallow groove or crevice between the light and the heavy chains, in close proximity to the polypeptide segments containing the hypervariable regions. Vitamin K 1 91-103 FA complementation group B Homo sapiens 104-107 1142015-7 1975 Cycloheximide also completely blocked the effect of physiological doses (10 mug) of phylloquinone upon prothrombin synthesis, but only partially blocked the effect of pharmacological doses (2.5 mg) of phylloquinone, suggesting an antagonism between cycloheximide and vitamin K at the ribosomal level. Vitamin K 1 84-97 coagulation factor II, thrombin Gallus gallus 103-114 13287765-0 1955 [Influence of massive doses if vitamin K1 on the coagulation factors prothrombin, factor V and factor VII in liver diseases]. Vitamin K 1 31-41 coagulation factor II, thrombin Homo sapiens 69-105 13786724-0 1961 The reduction of cytochrome c by reduced vitamin K1. Vitamin K 1 41-51 cytochrome c, somatic Homo sapiens 17-29 32822810-2 2020 We evaluated the suitability of ester derivatives of phyllohydroquinone (PKH), the active form of PK, for topical application to overcome the abovementioned problems of PK. Vitamin K 1 53-71 pyridoxal kinase Homo sapiens 73-76 13459653-0 1957 [Changes in prothrombin levels in fetal blood after the administration of vitamin K1 (2-methyl-3-phytyl-1, 4-naphthoquinone) in labor]. Vitamin K 1 74-84 coagulation factor II, thrombin Homo sapiens 12-23 13459653-0 1957 [Changes in prothrombin levels in fetal blood after the administration of vitamin K1 (2-methyl-3-phytyl-1, 4-naphthoquinone) in labor]. Vitamin K 1 86-123 coagulation factor II, thrombin Homo sapiens 12-23 33045823-11 2021 The results of statistical analysis showed that vitamin K1 and K2 levels were correlated with TNF-alpha, IL-1beta and IL-6 levels. Vitamin K 1 48-58 tumor necrosis factor Homo sapiens 94-103 33045823-11 2021 The results of statistical analysis showed that vitamin K1 and K2 levels were correlated with TNF-alpha, IL-1beta and IL-6 levels. Vitamin K 1 48-58 interleukin 1 alpha Homo sapiens 105-113 33045823-11 2021 The results of statistical analysis showed that vitamin K1 and K2 levels were correlated with TNF-alpha, IL-1beta and IL-6 levels. Vitamin K 1 48-58 interleukin 6 Homo sapiens 118-122 33454929-4 2021 Additionally, higher plasma levels of vitamin K1 have been associated with lower T2DM risk and decreased insulin resistance, and supplementation trials also suggest a positive influence of vitamin K on glucose regulation. Vitamin K 1 38-48 insulin Homo sapiens 105-112 32541171-2 2020 We assessed the efficacy and safety of vitamin K1(VK1)ointment for acneiform eruptions induced by anti-EGFR antibody treatment. Vitamin K 1 39-49 epidermal growth factor receptor Homo sapiens 103-107 32090699-4 2020 Differential DNA methylation was identified in multiple regions with previously unknown relationships to phylloquinone absorption and metabolism, such as at the TMEM263 locus. Vitamin K 1 105-118 transmembrane protein 263 Homo sapiens 161-168 32090699-5 2020 A hypothesis-driven analysis of lipid-related genes highlighted a site in the NPC1L1 gene, supplementing existing evidence for its role in phylloquinone absorption. Vitamin K 1 139-152 NPC1 like intracellular cholesterol transporter 1 Homo sapiens 78-84 32455149-3 2020 Green leafy vegetables are a rich source of vitamin K1, which is known to have large effects on osteoblasts and osteocalcin (OC) metabolism. Vitamin K 1 44-54 bone gamma-carboxyglutamate protein Homo sapiens 112-123 32612091-9 2020 Serum levels of BAP and TRACP-5b were significantly increased after vitamin K1 therapy. Vitamin K 1 68-78 SIL1 nucleotide exchange factor Homo sapiens 16-19 32244313-3 2020 Vitamin K1 and menaquinone (MK)-4 has been shown to decrease osteocalcin (OC) gamma-carboxylation at RDI levels. Vitamin K 1 0-10 bone gamma-carboxyglutamate protein Homo sapiens 61-72 32612091-9 2020 Serum levels of BAP and TRACP-5b were significantly increased after vitamin K1 therapy. Vitamin K 1 68-78 acid phosphatase 5, tartrate resistant Homo sapiens 24-32 30609653-0 2019 Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1. Vitamin K 1 25-38 vitamin K epoxide reductase complex subunit 1 Homo sapiens 115-121 31134657-0 2019 Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. Vitamin K 1 102-112 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 27-33 31134657-0 2019 Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. Vitamin K 1 102-112 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 49-55 31134657-1 2019 The objective of this study was to evaluate whether cytochrome P450 (CYP)4F2 is involved in the exposure of vitamin K1 through a drug interaction study with ketoconazole, a CYP4F2 inhibitor, and a pharmacogenetic study with CYP4F2*3. Vitamin K 1 108-118 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 52-76 31134657-1 2019 The objective of this study was to evaluate whether cytochrome P450 (CYP)4F2 is involved in the exposure of vitamin K1 through a drug interaction study with ketoconazole, a CYP4F2 inhibitor, and a pharmacogenetic study with CYP4F2*3. Vitamin K 1 108-118 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 173-179 31134657-1 2019 The objective of this study was to evaluate whether cytochrome P450 (CYP)4F2 is involved in the exposure of vitamin K1 through a drug interaction study with ketoconazole, a CYP4F2 inhibitor, and a pharmacogenetic study with CYP4F2*3. Vitamin K 1 108-118 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 224-230 31134657-6 2019 CYP4F2*3 polymorphism also affected plasma levels of vitamin K1 and its pharmacokinetics in a gene dose-dependent manner. Vitamin K 1 53-63 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 0-6 31134657-8 2019 This study revealed that ketoconazole and CYP4F2*3 polymorphism substantially increased the exposure of vitamin K1 in humans. Vitamin K 1 104-114 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 42-48 31134657-9 2019 These findings provide a plausible explanation for variations in warfarin dose requirements resulting from interindividual variations in vitamin K1 exposure due to CYP4F2-related drug interactions and genetic polymorphisms. Vitamin K 1 137-147 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 164-170 31538831-7 2019 Total MGP level was significantly associated with levels of vitamin K1 corrected for triglycerides (p <0 .001) and vitamin K2 <= 0.05 ng/ml (p < 0.05) in all subjects. Vitamin K 1 60-70 matrix Gla protein Homo sapiens 6-9 31601211-1 2019 BACKGROUND: With a variety of physiological and pharmacological functions, menaquinone is an essential prenylated product that can be endogenously converted from phylloquinone (VK1) or menadione (VK3) via the expression of Homo sapiens UBIAD1 (HsUBIAD1). Vitamin K 1 162-175 UbiA prenyltransferase domain containing 1 Homo sapiens 236-242 31173816-5 2019 In addition, the mRNA expression ratio of osteoprotegerin and the receptor activator of nuclear factor-kB ligand was also dramatically increased by treatment with vitamin K1 (62%), menaquinone-4 (247%), and menaquinone-7 (329%), suggesting that vitamin K may suppress the formation of osteoclast by up-regulating the ratio of osteoprotegerin/receptor activator of nuclear factor-kB ligand in osteoblasts. Vitamin K 1 163-173 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 42-57 31173816-5 2019 In addition, the mRNA expression ratio of osteoprotegerin and the receptor activator of nuclear factor-kB ligand was also dramatically increased by treatment with vitamin K1 (62%), menaquinone-4 (247%), and menaquinone-7 (329%), suggesting that vitamin K may suppress the formation of osteoclast by up-regulating the ratio of osteoprotegerin/receptor activator of nuclear factor-kB ligand in osteoblasts. Vitamin K 1 163-173 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 326-341 31173816-6 2019 These results provide compelling evidence that vitamin K1, menaquinone-4, and menaquinone-7 all can promote bone health, which might be associated with elevations in the osteoprotegerin/receptor activator of nuclear factor-kB ligand ratio. Vitamin K 1 47-57 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) Mus musculus 170-185 31312208-1 2019 Two phylloquinone molecules (A 1), one being predominantly coordinated by PsaA subunit residues (A 1A) the other by those of PsaB (A 1B), act as intermediates in the two parallel electron transfer chains of Photosystem I. Vitamin K 1 4-17 fatty acid amide hydrolase Homo sapiens 125-129 31312208-1 2019 Two phylloquinone molecules (A 1), one being predominantly coordinated by PsaA subunit residues (A 1A) the other by those of PsaB (A 1B), act as intermediates in the two parallel electron transfer chains of Photosystem I. Vitamin K 1 4-17 alpha-1-B glycoprotein Homo sapiens 131-135 30609653-4 2019 Here we present a molecular modeling study of vitamin K1, menaquinones 4, 7 (MK4, MK7), and K3 structural interactions with VKORC1. Vitamin K 1 46-56 vitamin K epoxide reductase complex subunit 1 Homo sapiens 124-130 30609653-9 2019 Our results revealed VKORC1"s ability to recycle both phylloquinone and some menaquinones, and also highlighted the importance of vitamin K"s hydrophobic tail size and membrane interactions. Vitamin K 1 54-67 vitamin K epoxide reductase complex subunit 1 Homo sapiens 21-27 31604989-0 2019 Vitamin K1 prevents diabetic cataract by inhibiting lens aldose reductase 2 (ALR2) activity. Vitamin K 1 0-10 aldo-keto reductase family 1 member B Homo sapiens 77-81 31604989-5 2019 Our results from protein docking and spectrofluorimetric analyses clearly show that vitamin K1 is a potent inhibitor of ALR2 and this inhibition is primarily mediated by the blockage of DL-glyceraldehyde binding to ALR2. Vitamin K 1 84-94 aldo-keto reductase family 1 member B Homo sapiens 120-124 31604989-5 2019 Our results from protein docking and spectrofluorimetric analyses clearly show that vitamin K1 is a potent inhibitor of ALR2 and this inhibition is primarily mediated by the blockage of DL-glyceraldehyde binding to ALR2. Vitamin K 1 84-94 aldo-keto reductase family 1 member B Homo sapiens 215-219 31604989-6 2019 At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the enzyme. Vitamin K 1 44-54 2,4-dienoyl-CoA reductase 1 Homo sapiens 71-76 31604989-6 2019 At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the enzyme. Vitamin K 1 44-54 aldo-keto reductase family 1 member B Homo sapiens 93-97 31604989-6 2019 At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the enzyme. Vitamin K 1 125-135 2,4-dienoyl-CoA reductase 1 Homo sapiens 71-76 31604989-6 2019 At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the enzyme. Vitamin K 1 125-135 aldo-keto reductase family 1 member B Homo sapiens 93-97 31604989-7 2019 Another deduction that we can derive from the experiments performed with pure protein is that ALR2 has three levels of affinity, first for NADPH, second for vitamin K1 and third for the substrate DL-glyceraldehyde. Vitamin K 1 157-167 aldo-keto reductase family 1 member B Homo sapiens 94-98 31604989-9 2019 Overall, our study shows the potential of vitamin K1 as an ALR2 inhibitor which primarily blocks enzyme activity by inhibiting substrate interaction of the enzyme. Vitamin K 1 42-52 aldo-keto reductase family 1 member B Homo sapiens 59-63 31604989-10 2019 Further structural studies are needed to fully comprehend the exact nature of binding and inhibition of ALR2 by vitamin K1 that could open up possibilities of its therapeutic application. Vitamin K 1 112-122 aldo-keto reductase family 1 member B Homo sapiens 104-108 30051471-3 2019 ISOCHORISMATE SYNTHASE 1 (ICS1) is known as a crucial enzyme required for synthesis of salicylic acid and phylloquinone, one of the components of the photosystem I complex. Vitamin K 1 106-119 ADC synthase superfamily protein Arabidopsis thaliana 0-24 30051471-3 2019 ISOCHORISMATE SYNTHASE 1 (ICS1) is known as a crucial enzyme required for synthesis of salicylic acid and phylloquinone, one of the components of the photosystem I complex. Vitamin K 1 106-119 ADC synthase superfamily protein Arabidopsis thaliana 26-30 31639794-0 2019 Vitamin K1 Inhibition of Renal Crystal Formation through Matrix Gla Protein in the Kidney. Vitamin K 1 0-10 matrix Gla protein Rattus norvegicus 57-75 30609653-0 2019 Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1. Vitamin K 1 40-50 vitamin K epoxide reductase complex subunit 1 Homo sapiens 115-121 30609653-1 2019 Vitamin K family molecules-phylloquinone (K1), menaquinone (K2), and menadione (K3)-act as gamma-glutamyl carboxylase (GGCX)-exclusive cofactors in their hydroquinone state, activating proteins of main importance for blood coagulation in the liver and for arterial calcification prevention and energy metabolism in extrahepatic tissues. Vitamin K 1 27-40 gamma-glutamyl carboxylase Homo sapiens 91-117 30609653-1 2019 Vitamin K family molecules-phylloquinone (K1), menaquinone (K2), and menadione (K3)-act as gamma-glutamyl carboxylase (GGCX)-exclusive cofactors in their hydroquinone state, activating proteins of main importance for blood coagulation in the liver and for arterial calcification prevention and energy metabolism in extrahepatic tissues. Vitamin K 1 27-40 gamma-glutamyl carboxylase Homo sapiens 119-123 30786829-7 2018 In the vitamin K1 group, a 27 % decrease in serum levels of IL-6 (P = 0.006) and a 13 % decrease in DAS-28 (P = 0.041) were observed. Vitamin K 1 7-17 interleukin 6 Homo sapiens 60-64 29955705-2 2017 Menaquinones (vitamin K-2) are another class of vitamin K compounds that differ from phylloquinone in the length and saturation of their side chain, but they have not been well characterized in foods. Vitamin K 1 85-98 RBPJ pseudogene 3 Homo sapiens 22-25 30319412-0 2018 Computational Insight Into Vitamin K1 omega-Hydroxylation by Cytochrome P450 4F2. Vitamin K 1 27-37 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 61-80 29470830-0 2018 Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. Vitamin K 1 115-125 insulin like growth factor 1 Homo sapiens 22-26 30446344-12 2018 UBIAD1 encodes the protein domain-containing UbiA prenyltransferase 1 which converts vitamin K1 into K2 and is involved in the cholesterol synthesis pathway. Vitamin K 1 85-95 UbiA prenyltransferase domain containing 1 Homo sapiens 0-6 30429362-8 2018 In addition, the mono-ADP-ribosylation inhibitors vitamin K1 and novobiocin inhibited oligomerization of TRIM72, the mechanism by which TRIM72 is recruited to the site of injury. Vitamin K 1 50-60 tripartite motif-containing 72 Mus musculus 105-111 30429362-8 2018 In addition, the mono-ADP-ribosylation inhibitors vitamin K1 and novobiocin inhibited oligomerization of TRIM72, the mechanism by which TRIM72 is recruited to the site of injury. Vitamin K 1 50-60 tripartite motif-containing 72 Mus musculus 136-142 28335649-9 2018 In response to vitamin K1 injection, GAS6 levels increased in preterm newborns (10.50 +- 5.28 ng/mL) (p < .05), but not in term newborns (9.12 +- 3.42 ng/mL, p > .05). Vitamin K 1 15-25 growth arrest specific 6 Homo sapiens 37-41 28335649-10 2018 CONCLUSION: This pilot study provided, to the best of our knowledge, the first report that GAS6 levels increased significantly after vitamin K1 prophylaxis in preterm newborns but not in term infants. Vitamin K 1 133-143 growth arrest specific 6 Homo sapiens 91-95 29175667-0 2018 Vitamin K1 inversely correlates with glycemia and insulin resistance in patients with type 2 diabetes (T2D) and positively regulates SIRT1/AMPK pathway of glucose metabolism in liver of T2D mice and hepatocytes cultured in high glucose. Vitamin K 1 0-10 sirtuin 1 Homo sapiens 133-138 26333893-11 2015 Vitamin K1 inhibited renal inflammation by reducing nuclear factor-kappaB and inducible nitric oxide synthase. Vitamin K 1 0-10 nitric oxide synthase 2 Rattus norvegicus 78-109 29263734-3 2017 There are two main kinds of vitamin K: Phylloquinone (or PK) and Menaquinones (MKn), both act as co-enzyme of y-glutamyl carboxylase (GGCX) transforming under-carboxylated in carboxylated vitamin K dependent proteins, such as Bone Gla Protein (or Osteocalcin) and Matrix Gla Protein. Vitamin K 1 39-52 gamma-glutamyl carboxylase Mus musculus 134-138 29263734-3 2017 There are two main kinds of vitamin K: Phylloquinone (or PK) and Menaquinones (MKn), both act as co-enzyme of y-glutamyl carboxylase (GGCX) transforming under-carboxylated in carboxylated vitamin K dependent proteins, such as Bone Gla Protein (or Osteocalcin) and Matrix Gla Protein. Vitamin K 1 39-52 bone gamma-carboxyglutamate protein 2 Mus musculus 247-258 27681307-10 2016 Delta2GGCX might be responsible for two unexpected clinical observations in the patient: (i) increased plasma osteocalcin levels following vitamin K1 supplementation; and (ii) a mild non-bleeding phenotype. Vitamin K 1 139-149 bone gamma-carboxyglutamate protein Homo sapiens 110-121 27462768-6 2016 Higher vitamin K1 was observed in CYP4F2 V433M polymorphism. Vitamin K 1 7-17 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 34-40 26224411-8 2016 Furthermore, we showed that the GGPPS11 protein physically interacts with enzymes that use GGPP for the production of carotenoids, chlorophylls, tocopherols, phylloquinone, and plastoquinone. Vitamin K 1 158-171 geranylgeranyl pyrophosphate synthase 1 Arabidopsis thaliana 32-39 28220270-5 2017 In contrast, serum eotaxin levels were greater than threefold higher in the patient with vitamin K1-induced morphea compared to patients with idiopathic morphea. Vitamin K 1 89-99 C-C motif chemokine ligand 11 Homo sapiens 19-26 27061505-12 2016 Considering only rs2108622, which is functionally relevant to vitamin K1 , the association for CAD/MI was stronger (OR, 1.21; 95% CI, 1.08-1.36). Vitamin K 1 62-72 aconitate decarboxylase 1 Homo sapiens 95-101 27000106-11 2016 (2) Undercarboxylated matrix Gla protein level is a poor surrogate for functional vitamin K1 deficiency. Vitamin K 1 82-92 matrix Gla protein Homo sapiens 22-40 26239439-15 2015 Long-acting anticoagulant rodenticides have an extremely high affinity for VKOR compared with warfarin, characterized by rebound coagulopathy and bleeding after initial treatment and the need for high-dose, long-term therapy with vitamin K1. Vitamin K 1 230-240 vitamin K epoxide reductase complex subunit 1 Homo sapiens 75-79 26333893-12 2015 Interleukin-10 levels were increased in renal tissues, suggesting the ability of vitamin K1 to trigger antiinflammatory state. Vitamin K 1 81-91 interleukin 10 Rattus norvegicus 0-14 25782427-0 2015 The effect of vitamin K1 supplementation on sensitivity and insulin resistance via osteocalcin in prediabetic women: a double-blind randomized controlled clinical trial. Vitamin K 1 14-24 bone gamma-carboxyglutamate protein Homo sapiens 83-94 26023160-1 2015 Mutation of Arabidopsis thaliana NAD(P)H DEHYDROGENASE C1 (NDC1; At5g08740) results in the accumulation of demethylphylloquinone, a late biosynthetic intermediate of vitamin K1. Vitamin K 1 166-176 NAD(P)H dehydrogenase C1 Arabidopsis thaliana 33-57 25782427-9 2015 CONCLUSIONS: The results of this study demonstrated that vitamin K1 supplementation for 4 weeks did not affect insulin resistance in premenopausal and prediabetic women but had beneficial effects on glycemic status and insulin sensitivity. Vitamin K 1 57-67 insulin Homo sapiens 219-226 26023160-1 2015 Mutation of Arabidopsis thaliana NAD(P)H DEHYDROGENASE C1 (NDC1; At5g08740) results in the accumulation of demethylphylloquinone, a late biosynthetic intermediate of vitamin K1. Vitamin K 1 166-176 NAD(P)H dehydrogenase C1 Arabidopsis thaliana 59-63 25466668-0 2015 Vitamin K1 alleviates streptozotocin-induced type 1 diabetes by mitigating free radical stress, as well as inhibiting NF-kappaB activation and iNOS expression in rat pancreas. Vitamin K 1 0-10 nitric oxide synthase 2 Rattus norvegicus 143-147 25654061-3 2015 Thus, the purpose of the present study was to examine the possible role of adiponectin as a mediator of glucose homeostasis following phylloquinone supplementation in premonopause women with prediabetes. Vitamin K 1 134-147 adiponectin, C1Q and collagen domain containing Homo sapiens 75-86 25654061-7 2015 RESULTS: Phylloquinone supplementation significantly increased serum adiponectin concentration (1.24 +- 1.90 compared with -0.27 +- 1.08 mug/ml), and did not alter total osteocalcin (0.50 +- 4.11 compared with 0.13 +- 1.85 ng/ml) and leptin (-0.29 +- 8.23 compared with -1.15 +- 5.25 ng/ml) compared with placebo. Vitamin K 1 9-22 adiponectin, C1Q and collagen domain containing Homo sapiens 69-80 25654061-7 2015 RESULTS: Phylloquinone supplementation significantly increased serum adiponectin concentration (1.24 +- 1.90 compared with -0.27 +- 1.08 mug/ml), and did not alter total osteocalcin (0.50 +- 4.11 compared with 0.13 +- 1.85 ng/ml) and leptin (-0.29 +- 8.23 compared with -1.15 +- 5.25 ng/ml) compared with placebo. Vitamin K 1 9-22 leptin Homo sapiens 234-240 25466668-6 2015 RESULTS: Treatment of STZ-induced type 1 diabetic rats with vitamin K1 reduced oxidative stress, enhanced antioxidants, and inhibited aldose reductase in pancreas. Vitamin K 1 60-70 aldo-keto reductase family 1 member B1 Rattus norvegicus 134-150 25466668-10 2015 To understand the mechanism involved in vitamin K1 mediated changes, we performed immunohistochemical analyses for NF-kappaB and iNOS enzyme. Vitamin K 1 40-50 nitric oxide synthase 2 Rattus norvegicus 129-133 25466668-11 2015 Vitamin K1 was shown to suppress NF-kappaB activation and iNOS expression in the islets upon administration of STZ. Vitamin K 1 0-10 nitric oxide synthase 2 Rattus norvegicus 58-62 25181575-2 2014 By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 mug of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. Vitamin K 1 107-120 bone gamma-carboxyglutamate protein Homo sapiens 189-200 25228690-6 2014 Anti-human SR-BI antibodies and BLT1 (a chemical inhibitor of lipid transport via SR-BI) blocked up to 85% of vitamin K1 uptake. Vitamin K 1 110-120 scavenger receptor class B, member 1 Mus musculus 11-16 25228690-6 2014 Anti-human SR-BI antibodies and BLT1 (a chemical inhibitor of lipid transport via SR-BI) blocked up to 85% of vitamin K1 uptake. Vitamin K 1 110-120 leukotriene B4 receptor 1 Mus musculus 32-36 25228690-6 2014 Anti-human SR-BI antibodies and BLT1 (a chemical inhibitor of lipid transport via SR-BI) blocked up to 85% of vitamin K1 uptake. Vitamin K 1 110-120 scavenger receptor class B, member 1 Mus musculus 82-87 25228690-7 2014 BLT1 also decreased phylloquinone apical efflux by ~80%. Vitamin K 1 20-33 leukotriene B4 receptor 1 Mus musculus 0-4 25228690-8 2014 Transfection of HEK cells with SR-BI and CD36 significantly enhanced vitamin K1 uptake, which was subsequently decreased by the addition of BLT1 or sulfo-N-succinimidyl oleate (CD36 inhibitor), respectively. Vitamin K 1 69-79 scavenger receptor class B, member 1 Mus musculus 31-36 25228690-8 2014 Transfection of HEK cells with SR-BI and CD36 significantly enhanced vitamin K1 uptake, which was subsequently decreased by the addition of BLT1 or sulfo-N-succinimidyl oleate (CD36 inhibitor), respectively. Vitamin K 1 69-79 leukotriene B4 receptor 1 Mus musculus 140-144 25228690-10 2014 In vivo, the phylloquinone postprandial response was significantly higher, and the proximal intestine mucosa phylloquinone content 4 h after gavage was increased in mice overexpressing SR-BI compared with controls. Vitamin K 1 13-26 scavenger receptor class B, member 1 Mus musculus 185-190 25228690-10 2014 In vivo, the phylloquinone postprandial response was significantly higher, and the proximal intestine mucosa phylloquinone content 4 h after gavage was increased in mice overexpressing SR-BI compared with controls. Vitamin K 1 109-122 scavenger receptor class B, member 1 Mus musculus 185-190 24874867-7 2014 Analysis of reactive oxygen species (ROS)-scavenging enzymes expression showed that suppression of SA and phylloquinone synthesis in the chloroplasts of the mpk4 mutant caused imbalances in ROS homeostasis which were more pronounced in mpk4/ics1 than in mpk4. Vitamin K 1 106-119 MAP kinase 4 Arabidopsis thaliana 157-161 24342502-2 2014 Interventional studies showed that vitamin K1 provided significant improvement in undercarboxylated osteocalcin (ucOC) levels in postmenopausal women with normal bone mineral density (BMD); however, there are inconsistent results in women with low BMD. Vitamin K 1 35-45 bone gamma-carboxyglutamate protein Homo sapiens 100-111 24742111-5 2014 In addition, alpha-SMA and CK19 expression was significantly reduced by vitamin K1 treatment in bile duct-ligated rats. Vitamin K 1 72-82 actin gamma 2, smooth muscle Rattus norvegicus 19-22 24742111-5 2014 In addition, alpha-SMA and CK19 expression was significantly reduced by vitamin K1 treatment in bile duct-ligated rats. Vitamin K 1 72-82 keratin 19 Rattus norvegicus 27-31 24594861-9 2014 Following treatment with vitamin K1 injection, the release of histamine and beta-hexosaminidase by rat basophilic leukemia-2H3 cells as well as the rate of apoptosis increased. Vitamin K 1 25-35 O-GlcNAcase Rattus norvegicus 76-95 24085302-3 2013 There is evidence that UBIAD1 has a weak side chain cleavage activity for phylloquinone but a strong prenylation activity for menadione (vitamin K3), which has long been postulated as an intermediate in this conversion. Vitamin K 1 74-87 UbiA prenyltransferase domain containing 1 Rattus norvegicus 23-29 24138531-3 2013 Although cytochrome P450 (CYP) 4F2 activity is recognized as an important determinant of phylloquinone (K1) metabolism, the enzymes involved in menaquinone catabolism have not been studied previously. Vitamin K 1 89-102 solute carrier family 3 member 2 Homo sapiens 31-34 24489112-5 2014 In parallel, a novel human enzyme that participates in the cellular conversion of phylloquinone to menaquinone (MK)-4 was identified as UbiA prenyltransferase-containing domain 1 (UBIAD1). Vitamin K 1 82-95 UbiA prenyltransferase domain containing 1 Homo sapiens 136-178 24489112-5 2014 In parallel, a novel human enzyme that participates in the cellular conversion of phylloquinone to menaquinone (MK)-4 was identified as UbiA prenyltransferase-containing domain 1 (UBIAD1). Vitamin K 1 82-95 UbiA prenyltransferase domain containing 1 Homo sapiens 180-186 23298335-0 2013 Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Vitamin K 1 28-41 insulin Homo sapiens 98-105 23650179-0 2013 omega-Hydroxylation of phylloquinone by CYP4F2 is not increased by alpha-tocopherol. Vitamin K 1 23-36 cytochrome P450 family 4 subfamily F member 2 Homo sapiens 40-46 22035385-0 2013 Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. Vitamin K 1 0-14 epidermal growth factor receptor Homo sapiens 32-36 22035385-4 2013 OBJECTIVE: To assess the possible effect of topical phytomenadione (vitamin K1 ) pre-treatment in diminishing the extent and severity of acne-like follicular rash associated with epidermal growth factor receptor inhibitor therapy. Vitamin K 1 52-66 epidermal growth factor receptor Homo sapiens 179-211 22035385-4 2013 OBJECTIVE: To assess the possible effect of topical phytomenadione (vitamin K1 ) pre-treatment in diminishing the extent and severity of acne-like follicular rash associated with epidermal growth factor receptor inhibitor therapy. Vitamin K 1 68-78 epidermal growth factor receptor Homo sapiens 179-211 22864379-0 2013 VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation. Vitamin K 1 58-71 vitamin K epoxide reductase complex subunit 1 Homo sapiens 0-6 22864379-0 2013 VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation. Vitamin K 1 73-83 vitamin K epoxide reductase complex subunit 1 Homo sapiens 0-6 22864379-11 2013 The influence of the VKORC1 promoter polymorphism c.-1639 G > A on the pharmacokinetic properties of phylloquinone could be demonstrated in humans. Vitamin K 1 104-117 vitamin K epoxide reductase complex subunit 1 Homo sapiens 21-27 23298335-8 2013 CONCLUSION: These results show that dietary phylloquinone intake is associated with an improvement of cytokines and other markers related to insulin resistance and diabetes, thus extending the potential protection by dietary phylloquinone on chronic inflammatory diseases. Vitamin K 1 44-57 insulin Homo sapiens 141-148 20599721-8 2010 We propose that K516 acetylation may serve to modulate important kinase-independent functions of S6K1 in response to growth factor signalling. Vitamin K 1 16-20 ribosomal protein S6 kinase B1 Homo sapiens 97-101 22437558-6 2012 Despite baseline differences in measures of vitamin K status, plasma phylloquinone tended to increase (P = 0.07) and the percentage of uncarboxylated osteocalcin and uncarboxylated prothrombin both improved with phylloquinone supplementation (P < 0.007), regardless of age group or sex. Vitamin K 1 212-225 bone gamma-carboxyglutamate protein Homo sapiens 150-161 21734462-0 2011 c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Vitamin K 1 90-100 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 0-5 21734462-0 2011 c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Vitamin K 1 90-100 AKT serine/threonine kinase 1 Homo sapiens 6-9 21734462-0 2011 c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Vitamin K 1 90-100 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 53-58 21188521-0 2011 Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Vitamin K 1 24-34 alpha fetoprotein Homo sapiens 38-41 21188521-9 2011 Mechanism studies showed that vitamin K1 induced phosphorylation of JNK and c-Jun and caspase-mediated apoptosis. Vitamin K 1 30-40 mitogen-activated protein kinase 8 Homo sapiens 68-71 21188521-9 2011 Mechanism studies showed that vitamin K1 induced phosphorylation of JNK and c-Jun and caspase-mediated apoptosis. Vitamin K 1 30-40 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 76-81 21188521-10 2011 CONCLUSIONS: Vitamin K1 was non-toxic at high doses, strongly inhibited plasma DCP levels, but weakly suppressed AFP levels. Vitamin K 1 13-23 alpha fetoprotein Homo sapiens 113-116 20626653-0 2010 A bimodular oxidoreductase mediates the specific reduction of phylloquinone (vitamin K1) in chloroplasts. Vitamin K 1 62-75 thioredoxin reductase 1 Homo sapiens 12-26 20626653-0 2010 A bimodular oxidoreductase mediates the specific reduction of phylloquinone (vitamin K1) in chloroplasts. Vitamin K 1 77-87 thioredoxin reductase 1 Homo sapiens 12-26 22520038-0 2012 Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. Vitamin K 1 0-10 zinc fingers and homeoboxes 2 Homo sapiens 118-121 22520038-0 2012 Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. Vitamin K 1 0-10 mitogen-activated protein kinase kinase 7 Homo sapiens 122-125 22520038-0 2012 Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. Vitamin K 1 0-10 mitogen-activated protein kinase 1 Homo sapiens 126-129 21734462-4 2011 We found that whereas lower concentration of vitamin K1 (25 muM) or sorafenib (2.5 muM) alone slightly induced c-Raf phosphorylation at both Ser-43 and Ser-259, combination vitamin K1 plus sorafenib resulted in strong c-Raf phosphorylation at these two serine residues. Vitamin K 1 45-55 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 111-116 21734462-4 2011 We found that whereas lower concentration of vitamin K1 (25 muM) or sorafenib (2.5 muM) alone slightly induced c-Raf phosphorylation at both Ser-43 and Ser-259, combination vitamin K1 plus sorafenib resulted in strong c-Raf phosphorylation at these two serine residues. Vitamin K 1 45-55 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 218-223 21734462-5 2011 A Raf kinase activity assay confirmed that combination vitamin K1 plus sorafenib had a synergistic inhibitory effect on it. Vitamin K 1 55-65 zinc fingers and homeoboxes 2 Homo sapiens 2-5 21734462-8 2011 However, vitamin K1 enhanced sorafenib-induced c-Met phosphorylation at Tyr-1349, a DEP-1 protein phosphatase acting site, and consequently induced phosphorylation of PI3K-Akt. Vitamin K 1 9-19 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 47-52 21734462-8 2011 However, vitamin K1 enhanced sorafenib-induced c-Met phosphorylation at Tyr-1349, a DEP-1 protein phosphatase acting site, and consequently induced phosphorylation of PI3K-Akt. Vitamin K 1 9-19 protein tyrosine phosphatase receptor type J Homo sapiens 84-89 21734462-8 2011 However, vitamin K1 enhanced sorafenib-induced c-Met phosphorylation at Tyr-1349, a DEP-1 protein phosphatase acting site, and consequently induced phosphorylation of PI3K-Akt. Vitamin K 1 9-19 AKT serine/threonine kinase 1 Homo sapiens 172-175 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 95-105 AKT serine/threonine kinase 1 Homo sapiens 58-61 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 95-105 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 132-137 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 95-105 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 198-203 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 95-105 AKT serine/threonine kinase 1 Homo sapiens 209-212 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 95-105 Raf-1 proto-oncogene, serine/threonine kinase Homo sapiens 251-256 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 300-310 AKT serine/threonine kinase 1 Homo sapiens 58-61 21734462-9 2011 Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth. Vitamin K 1 300-310 MET proto-oncogene, receptor tyrosine kinase Homo sapiens 198-203 22041909-0 2011 Vitamin K1 (phylloquinone) or vitamin K2 (menaquinone-4) induces intestinal alkaline phosphatase gene expression. Vitamin K 1 0-10 alkaline phosphatase 3, intestine, not Mn requiring Mus musculus 65-96 22041909-0 2011 Vitamin K1 (phylloquinone) or vitamin K2 (menaquinone-4) induces intestinal alkaline phosphatase gene expression. Vitamin K 1 12-25 alkaline phosphatase 3, intestine, not Mn requiring Mus musculus 65-96 20301194-9 2010 Vitamin K1 plus Sorafenib combination also resulted in elevated levels of activated c-Jun N-terminal kinase (JNK) and its substrates c-Jun and FasL. Vitamin K 1 0-10 Fas ligand Homo sapiens 143-147 20301194-9 2010 Vitamin K1 plus Sorafenib combination also resulted in elevated levels of activated c-Jun N-terminal kinase (JNK) and its substrates c-Jun and FasL. Vitamin K 1 0-10 mitogen-activated protein kinase 8 Homo sapiens 84-107 20301194-9 2010 Vitamin K1 plus Sorafenib combination also resulted in elevated levels of activated c-Jun N-terminal kinase (JNK) and its substrates c-Jun and FasL. Vitamin K 1 0-10 mitogen-activated protein kinase 8 Homo sapiens 109-112 20301194-9 2010 Vitamin K1 plus Sorafenib combination also resulted in elevated levels of activated c-Jun N-terminal kinase (JNK) and its substrates c-Jun and FasL. Vitamin K 1 0-10 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 84-89 18922041-11 2008 Daily vitamin K1 supplementation increased serum vitamin K1 levels by 10-fold, and decreased the percentage of undercarboxylated osteocalcin and total osteocalcin levels (bone formation marker). Vitamin K 1 6-16 bone gamma-carboxyglutamate protein Homo sapiens 129-140 19409369-0 2009 Protein-cofactor interactions in bioenergetic complexes: the role of the A1A and A1B phylloquinones in Photosystem I. Vitamin K 1 85-99 alpha-1-B glycoprotein Homo sapiens 81-84 19113922-12 2009 Phylloquinone and MK4 treatment reduced serum undercarboxylated osteocalcin but did not alter BSALP or NTX. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 64-75 19249875-0 2009 Role of the hydrogen bond from Leu722 to the A1A phylloquinone in photosystem I. Photosystem I (PS I) contains two molecules of phylloquinone that function as electron transfer cofactors at highly reducing midpoint potentials. Vitamin K 1 49-62 serpin family A member 1 Homo sapiens 45-48 19249875-0 2009 Role of the hydrogen bond from Leu722 to the A1A phylloquinone in photosystem I. Photosystem I (PS I) contains two molecules of phylloquinone that function as electron transfer cofactors at highly reducing midpoint potentials. Vitamin K 1 128-141 serpin family A member 1 Homo sapiens 45-48 18922041-11 2008 Daily vitamin K1 supplementation increased serum vitamin K1 levels by 10-fold, and decreased the percentage of undercarboxylated osteocalcin and total osteocalcin levels (bone formation marker). Vitamin K 1 6-16 bone gamma-carboxyglutamate protein Homo sapiens 151-162 18841274-4 2008 TRL-borne phylloquinone uptake by osteoblasts is an apoE-mediated process with the LRP1 receptor playing a predominant role. Vitamin K 1 10-23 apolipoprotein E Homo sapiens 52-56 18841274-4 2008 TRL-borne phylloquinone uptake by osteoblasts is an apoE-mediated process with the LRP1 receptor playing a predominant role. Vitamin K 1 10-23 LDL receptor related protein 1 Homo sapiens 83-87 18841274-6 2008 Both phylloquinone and MKs activate the steroid and xenobiotic receptor (SXR) that initiates their catabolism, but MK-4 specifically upregulates two genes suggesting a novel MK-4 signalling pathway. Vitamin K 1 5-18 nuclear receptor subfamily 1 group I member 2 Homo sapiens 40-71 18841274-6 2008 Both phylloquinone and MKs activate the steroid and xenobiotic receptor (SXR) that initiates their catabolism, but MK-4 specifically upregulates two genes suggesting a novel MK-4 signalling pathway. Vitamin K 1 5-18 nuclear receptor subfamily 1 group I member 2 Homo sapiens 73-76 18841274-11 2008 In humans, MK-7 has a greater efficacy than phylloquinone in carboxylating both liver and bone Gla proteins. Vitamin K 1 44-57 galactosidase alpha Homo sapiens 95-98 17082184-2 2006 The last step of phylloquinone synthesis in cyanobacteria is the methylation of 2-phytyl-1,4-naphthoquinone by the menG gene product. Vitamin K 1 17-30 S-adenosyl-L-methionine-dependent methyltransferases superfamily protein Arabidopsis thaliana 115-119 18689371-4 2008 RESULTS: Cross-sectionally, plasma phylloquinone was inversely associated with IL-6 and CRP, whereas serum %ucOC was inversely associated with IL-6. Vitamin K 1 35-48 interleukin 6 Homo sapiens 79-91 18689371-4 2008 RESULTS: Cross-sectionally, plasma phylloquinone was inversely associated with IL-6 and CRP, whereas serum %ucOC was inversely associated with IL-6. Vitamin K 1 35-48 interleukin 6 Homo sapiens 79-83 18689371-5 2008 Osteoprotegerin was associated positively with plasma phylloquinone and inversely with %ucOC. Vitamin K 1 54-67 TNF receptor superfamily member 11b Homo sapiens 0-15 18538644-10 2008 Most importantly, the injection of vitamin K1-enriched CR resulted in an increase of the degree of osteocalcin carboxylation in vivo while total osteocalcin concentrations remained unaffected, giving functional proof that osteoblasts process CR in vivo. Vitamin K 1 35-45 bone gamma-carboxyglutamate protein 2 Mus musculus 99-110 18614743-4 2008 DESIGN: We assessed the cross-sectional associations of self-reported phylloquinone (vitamin K(1)) intake with insulin sensitivity and glycemic status in the Framingham Offspring Cohort. Vitamin K 1 70-83 insulin Homo sapiens 111-118 18208520-0 2008 The AAE14 gene encodes the Arabidopsis o-succinylbenzoyl-CoA ligase that is essential for phylloquinone synthesis and photosystem-I function. Vitamin K 1 90-103 acyl-activating enzyme 14 Arabidopsis thaliana 4-9 18208520-3 2008 Here, we identify acyl-activating enzyme 14 (AAE14, At1g30520) as the o-succinylbenzoyl-coenzyme A (OSB-CoA) ligase acting in phylloquinone synthesis. Vitamin K 1 126-139 acyl-activating enzyme 14 Arabidopsis thaliana 18-43 18208520-3 2008 Here, we identify acyl-activating enzyme 14 (AAE14, At1g30520) as the o-succinylbenzoyl-coenzyme A (OSB-CoA) ligase acting in phylloquinone synthesis. Vitamin K 1 126-139 acyl-activating enzyme 14 Arabidopsis thaliana 45-50 17725326-0 2007 Contributions of the protein environment to the midpoint potentials of the A1 phylloquinones and the Fx iron-sulfur cluster in photosystem I. Electrostatic calculations have predicted that the partial negative charge associated with D575PsaB plays a significant role in modulating the midpoint potentials of the A1A and A1B phylloquinones in photosystem I. Vitamin K 1 78-92 alpha-1-B glycoprotein Homo sapiens 320-323 17725326-0 2007 Contributions of the protein environment to the midpoint potentials of the A1 phylloquinones and the Fx iron-sulfur cluster in photosystem I. Electrostatic calculations have predicted that the partial negative charge associated with D575PsaB plays a significant role in modulating the midpoint potentials of the A1A and A1B phylloquinones in photosystem I. Vitamin K 1 324-338 alpha-1-B glycoprotein Homo sapiens 320-323 17298708-5 2007 With increasing phylloquinone intake, the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001). Vitamin K 1 16-29 bone gamma-carboxyglutamate protein Homo sapiens 113-124 17298708-7 2007 Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo. Vitamin K 1 134-147 bone gamma-carboxyglutamate protein Homo sapiens 12-23 18252784-8 2008 The group that received the phylloquinone supplement had significantly higher phylloquinone and significantly lower percent undercarboxylated osteocalcin concentrations compared with the group that did not receive phylloquinone. Vitamin K 1 28-41 bone gamma-carboxyglutamate protein Homo sapiens 142-153 18208520-6 2008 Weak expression of an AAE14 transgene in mutant plants (controlled by the uninduced XVE promoter) resulted in chlorotic, slow-growing plants that accumulated an average of 4.7 pmol mg(-1) fresh weight of phylloquinone. Vitamin K 1 204-217 acyl-activating enzyme 14 Arabidopsis thaliana 22-27 18208520-8 2008 aae14-mutant plants were also able to synthesize phylloquinone when provided with 1,4-dihydroxy-2-naphthoate, an intermediate in phylloquinone synthesis downstream of the OSB-CoA ligase reaction. Vitamin K 1 49-62 acyl-activating enzyme 14 Arabidopsis thaliana 0-5 18208520-8 2008 aae14-mutant plants were also able to synthesize phylloquinone when provided with 1,4-dihydroxy-2-naphthoate, an intermediate in phylloquinone synthesis downstream of the OSB-CoA ligase reaction. Vitamin K 1 129-142 acyl-activating enzyme 14 Arabidopsis thaliana 0-5 16929463-1 2007 The main function of vitamin K1 is to act a co-factor for gamma-glutamyl carboxylase. Vitamin K 1 21-31 gamma-glutamyl carboxylase Rattus norvegicus 58-84 16469998-2 2006 Phylloquinone (K1) and menaquinone 4 (MK-4) and 7 (MK-7) are generally observed in human plasma; however, data are limited on their circulating concentrations and their associations with bone metabolism or with gamma-carboxylation of the osteocalcin molecule. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 238-249 16989769-0 2006 Bidirectional electron transfer in photosystem I: replacement of the symmetry-breaking tryptophan close to the PsaB-bound phylloquinone A1B with a glycine residue alters the redox properties of A1B and blocks forward electron transfer at cryogenic temperatures. Vitamin K 1 122-135 photosystem I P700 chlorophyll a apoprotein A2 Chlamydomonas reinhardtii 111-115 12888638-4 2003 Plasma phylloquinone, urinary gamma-carboxyglutamic acid excretion and gamma-carboxylation of hepatic (prothrombin) and extrahepatic proteins (osteocalcin) decreased in response to phylloquinone restriction (P < 0.001), demonstrating the production of subclinical vitamin K deficiency. Vitamin K 1 181-194 bone gamma-carboxyglutamate protein Homo sapiens 143-154 15686525-4 2005 The mutated nuclear gene encoded 1,4-dihydroxy-2-naphtoic acid phytyltransferase, an enzyme of phylloquinone biosynthesis, and high-performance liquid chromatography analysis revealed that the abc4 mutant contained no phylloquinone, and only about 3% plastoquinone. Vitamin K 1 95-108 UbiA prenyltransferase family protein Arabidopsis thaliana 193-197 15686525-4 2005 The mutated nuclear gene encoded 1,4-dihydroxy-2-naphtoic acid phytyltransferase, an enzyme of phylloquinone biosynthesis, and high-performance liquid chromatography analysis revealed that the abc4 mutant contained no phylloquinone, and only about 3% plastoquinone. Vitamin K 1 218-231 UbiA prenyltransferase family protein Arabidopsis thaliana 193-197 15514282-3 2004 We examined whether dietary intake of phylloquinone (vitamin K-1) and menaquinone (vitamin K-2) were related to aortic calcification and coronary heart disease (CHD) in the population-based Rotterdam Study. Vitamin K 1 38-51 keratin 1 Homo sapiens 61-64 15647823-0 2005 Expression of LRP1 by human osteoblasts: a mechanism for the delivery of lipoproteins and vitamin K1 to bone. Vitamin K 1 90-100 LDL receptor related protein 1 Homo sapiens 14-18 15647823-4 2005 We provide evidence that LRP1 plays an important role in the uptake of postprandial lipoproteins and vitamin K1 by human osteoblasts. Vitamin K 1 101-111 LDL receptor related protein 1 Homo sapiens 25-29 15647823-20 2005 Vitamin K1 uptake by hMSC-TERT-OB after incubation with CR-K1 was also shown to be sensitive to LPL stimulation and the LRP1 specific inhibitor lactoferrin. Vitamin K 1 0-10 telomerase reverse transcriptase Homo sapiens 26-30 15647823-20 2005 Vitamin K1 uptake by hMSC-TERT-OB after incubation with CR-K1 was also shown to be sensitive to LPL stimulation and the LRP1 specific inhibitor lactoferrin. Vitamin K 1 0-10 lipoprotein lipase Homo sapiens 96-99 15647823-20 2005 Vitamin K1 uptake by hMSC-TERT-OB after incubation with CR-K1 was also shown to be sensitive to LPL stimulation and the LRP1 specific inhibitor lactoferrin. Vitamin K 1 0-10 LDL receptor related protein 1 Homo sapiens 120-124 15647823-22 2005 CONCLUSION: Human osteoblasts express receptors of the LDLR family with a capacity for vitamin K1 uptake through CR endocytosis, a novel mechanism for the delivery of dietary lipids and lipophilic vitamins to human bone. Vitamin K 1 87-97 low density lipoprotein receptor Homo sapiens 55-59 15340366-1 2005 OBJECTIVE: To investigate plasma osteocalcin gamma-carboxylation and its relationship to plasma phylloquinone concentration and apolipoprotein E (apoE) genotype in women from three ethnic groups with differing osteoporotic fracture risk. Vitamin K 1 96-109 bone gamma-carboxyglutamate protein Homo sapiens 33-44 12172322-3 2002 METHODS AND RESULTS: Warfarin and vitamin K1 treatment for 4 or 8 weeks led to an elevation of PP, associated with increases in aortic calcium deposition and the ratio of collagen to elastin (C/E). Vitamin K 1 34-44 elastin Rattus norvegicus 183-190 12399278-0 2002 A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation. Vitamin K 1 7-20 bone gamma-carboxyglutamate protein Homo sapiens 59-70 12399278-2 2002 Phylloquinone supplementation increases osteocalcin gamma-carboxylation; however, the amount required to maximize carboxylation is not known. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 40-51 12399278-3 2002 OBJECTIVE: This study assessed the ability of various doses of phylloquinone (vitamin K(1)) to facilitate osteocalcin gamma-carboxylation. Vitamin K 1 63-76 bone gamma-carboxyglutamate protein Homo sapiens 106-117 12399278-12 2002 CONCLUSION: A daily phylloquinone intake of approximately 1000 micro g is required to maximally gamma-carboxylate circulating osteocalcin. Vitamin K 1 20-33 bone gamma-carboxyglutamate protein Homo sapiens 126-137 11489879-1 2001 The core of photosystem I (PS1) is composed of the two related integral membrane polypeptides, PsaA and PsaB, which bind two symmetrical branches of cofactors, each consisting of two chlorophylls and a phylloquinone, that potentially link the primary electron donor and the tertiary acceptor. Vitamin K 1 202-215 presenilin 1 Homo sapiens 27-30 11911978-0 2002 Novel effect of vitamin K(1) (phylloquinone) and vitamin K(2) (menaquinone) on promoting nerve growth factor-mediated neurite outgrowth from PC12D cells. Vitamin K 1 30-43 nerve growth factor Rattus norvegicus 89-108 12180675-6 2002 Mean recoveries of vitamin K1 isomers from spiked liver were 92 +/- 11% for cis-vitamin K1 and 106 +/- 5% for trans-vitamin K1. Vitamin K 1 19-29 keratin 1 Rattus norvegicus 88-98 11782837-10 2002 The serum concentration of vitamin K1 correlated positively with that of 25-OHD (r =.735, P <.0001), and negatively with undercarboxylated osteocalcin (r = -.751, P <.0001) and Hoehn and Yahr stages (r =.787, P <.0001). Vitamin K 1 27-37 bone gamma-carboxyglutamate protein Homo sapiens 139-150 11782837-12 2002 CONCLUSION: In functionally dependent women with PD, nutritional vitamin K1 deficiency is believed to reduce production of fully carboxylated osteocalcin, causing reduced BMD. Vitamin K 1 65-75 bone gamma-carboxyglutamate protein Homo sapiens 142-153 11706280-4 2001 Doses of vitamin K1 up to 15 times the current recommended dietary allowance have successfully been used to reduce the percentage of undercarboxylated osteocalcin in the circulation. Vitamin K 1 9-19 bone gamma-carboxyglutamate protein Homo sapiens 151-162 11489879-1 2001 The core of photosystem I (PS1) is composed of the two related integral membrane polypeptides, PsaA and PsaB, which bind two symmetrical branches of cofactors, each consisting of two chlorophylls and a phylloquinone, that potentially link the primary electron donor and the tertiary acceptor. Vitamin K 1 202-215 photosystem I P700 chlorophyll a apoprotein A1 Chlamydomonas reinhardtii 95-99 11489879-1 2001 The core of photosystem I (PS1) is composed of the two related integral membrane polypeptides, PsaA and PsaB, which bind two symmetrical branches of cofactors, each consisting of two chlorophylls and a phylloquinone, that potentially link the primary electron donor and the tertiary acceptor. Vitamin K 1 202-215 fatty acid amide hydrolase Homo sapiens 104-108 11489879-2 2001 In an effort to identify amino acid residues near the phylloquinone binding sites, all tryptophans and histidines that are conserved between PsaA and PsaB in the region of the 10th and 11th transmembrane alpha-helices were mutated in Chlamydomonas reinhardtii. Vitamin K 1 54-67 photosystem I P700 chlorophyll a apoprotein A1 Chlamydomonas reinhardtii 141-145 11489879-2 2001 In an effort to identify amino acid residues near the phylloquinone binding sites, all tryptophans and histidines that are conserved between PsaA and PsaB in the region of the 10th and 11th transmembrane alpha-helices were mutated in Chlamydomonas reinhardtii. Vitamin K 1 54-67 photosystem I P700 chlorophyll a apoprotein A2 Chlamydomonas reinhardtii 150-154 11489879-7 2001 These observations indicate that the A(1)(-) phylloquinone radical observed by EPR occupies the phylloquinone-binding site containing PsaA-Trp(693). Vitamin K 1 45-58 photosystem I P700 chlorophyll a apoprotein A1 Chlamydomonas reinhardtii 134-138 10479199-7 1999 The relative bioavailability of phylloquinone was defined by the difference in plasma phylloquinone, percentage serum undercarboxylated osteocalcin (%ucOC), and urinary gamma-carboxyglutamic acid in response to 5 d of supplementation. Vitamin K 1 32-45 bone gamma-carboxyglutamate protein Homo sapiens 136-147 11101481-10 2000 Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 44-55 11101481-12 2000 Phylloquinone supplementation reduced serum osteocalcin concentration but did not alter other markers of serum bone turnover. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 44-55 11121919-6 2000 RESULTS: Liver function tests and international normalized ratio were comparable between groups at entry into the study (P > 0.05), but serum albumin was significantly lower in the intravenous phytomenadione group following treatment (P < 0.05). Vitamin K 1 196-210 albumin Homo sapiens 145-152 10509895-4 1999 Stepwise linear regression methods determined that serum concentrations of both vitamin E and vitamin K1 could best be predicted by using equations excluding lipids but containing only apolipoprotein A1 and B concentrations. Vitamin K 1 94-104 apolipoprotein A1 Homo sapiens 185-202 9161943-11 1997 The carboxylation state of osteocalcin and PIVKA-II were the most sensitive indices of changes in vitamin K1 status. Vitamin K 1 98-108 bone gamma-carboxyglutamate protein Homo sapiens 27-38 9771550-3 1998 Vitamin K1, however, brought about an identical effect with Trp-P-2 only, while with CP an initial decrease of SCEs was followed by a statistically significant re-increase at higher concentrations. Vitamin K 1 0-10 polycystin 2, transient receptor potential cation channel Homo sapiens 60-67 9722271-2 1998 This cross-sectional study aimed to detect the levels of phylloquinone in GCF from healthy and diseased sites in subjects with adult periodontitis, in order to investigate further its potential role in the disease process. Vitamin K 1 57-70 GC-rich sequence DNA-binding factor 2 Homo sapiens 74-77 9722271-6 1998 The mean amount of phylloquinone in accumulated GCF from diseased sites was 406 pg/site and 80 pg/site from healthy sites (p=0.013). Vitamin K 1 19-32 GC-rich sequence DNA-binding factor 2 Homo sapiens 48-51 9722271-7 1998 When the amounts of phylloquinone in GCF were expressed as concentrations the values were 228 ng/ml and 3350 ng/ml for diseased and healthy sites respectively (p=0.084). Vitamin K 1 20-33 GC-rich sequence DNA-binding factor 2 Homo sapiens 37-40 9722271-8 1998 These findings suggest the levels of phylloquinone in GCF differs in periodontal health and disease in subjects with adult periodontitis. Vitamin K 1 37-50 GC-rich sequence DNA-binding factor 2 Homo sapiens 54-57 10194997-1 1998 AIM: To determine whether vitamin K1, which is routinely administered to neonates, could act as an exogenous oxidising agent and be partly responsible for haemolysis in glucose-6-phosphat-dehydrogenase (G-6-PD). Vitamin K 1 26-36 glucose-6-phosphate dehydrogenase Homo sapiens 169-201 10194997-1 1998 AIM: To determine whether vitamin K1, which is routinely administered to neonates, could act as an exogenous oxidising agent and be partly responsible for haemolysis in glucose-6-phosphat-dehydrogenase (G-6-PD). Vitamin K 1 26-36 glucose-6-phosphate dehydrogenase Homo sapiens 203-209 8599321-7 1996 The undercarboxylated osteocalcin concentration, shown previously to be responsive to depletion and repletion of phylloquinone, was compared with the other indexes to determine its reliability as an indicator of vitamin K nutritional status. Vitamin K 1 113-126 bone gamma-carboxyglutamate protein Homo sapiens 22-33 9083289-2 1997 Phylloquinone concentrations were significantly lower in the 23 patients with previous fractures compared to those without (0.93 vs. 1.50 nmol/liter, P < 0.003) and a smaller percentage of their serum osteocalcin was carboxylated (48.8 vs. 53.6%, P < 0.03). Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 204-215 9062529-0 1997 Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Vitamin K 1 133-146 bone gamma-carboxyglutamate protein Homo sapiens 17-28 7991564-6 1994 We found that the CA1 tissue from hippocampus possesses an ADPRT activity that is dramatically stimulated by NO and attenuated by two different inhibitors of mono-ADPRT activity, phylloquinone and nicotinamide. Vitamin K 1 179-192 carbonic anhydrase 1 Homo sapiens 18-21 8642455-6 1996 Another determinant of vitamin K1 concentration in serum is the presence of specific variants of apolipoprotein E (apoE). Vitamin K 1 23-33 apolipoprotein E Homo sapiens 97-113 8642455-6 1996 Another determinant of vitamin K1 concentration in serum is the presence of specific variants of apolipoprotein E (apoE). Vitamin K 1 23-33 apolipoprotein E Homo sapiens 115-119 8557941-0 1996 Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. Vitamin K 1 49-62 keratin 1 Homo sapiens 44-47 8557941-1 1996 OBJECTIVE: To identify important food sources and estimate dietary intake of vitamin K-1 (phylloquinone) in the American diet. Vitamin K 1 90-103 keratin 1 Homo sapiens 85-88 7638250-2 1995 The relative utilization of phylloquinone and menaquinone-9 (MK-9) as substrates for the microsomal vitamin K-dependent gamma-glutamyl carboxylase was determined in a rat model. Vitamin K 1 28-41 gamma-glutamyl carboxylase Rattus norvegicus 120-146 7991564-6 1994 We found that the CA1 tissue from hippocampus possesses an ADPRT activity that is dramatically stimulated by NO and attenuated by two different inhibitors of mono-ADPRT activity, phylloquinone and nicotinamide. Vitamin K 1 179-192 poly(ADP-ribose) polymerase 1 Homo sapiens 59-64 8304041-2 1993 It has been shown that rats maintained on chronic treatment with vitamin K1 and its antagonist warfarin exhibit a marked decrease in bone osteocalcin because noncarboxylated osteocalcin does not bind to bone hydroxyapatite. Vitamin K 1 65-75 bone gamma-carboxyglutamate protein Rattus norvegicus 138-149 8304041-2 1993 It has been shown that rats maintained on chronic treatment with vitamin K1 and its antagonist warfarin exhibit a marked decrease in bone osteocalcin because noncarboxylated osteocalcin does not bind to bone hydroxyapatite. Vitamin K 1 65-75 bone gamma-carboxyglutamate protein Rattus norvegicus 174-185 8393269-0 1993 Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Vitamin K 1 0-13 bone gamma-carboxyglutamate protein Homo sapiens 80-91 8393269-3 1993 Phylloquinone concentrations in plasma were related to apolipoprotein E genotype in the order E2 > E3 > E4. Vitamin K 1 0-13 apolipoprotein E Homo sapiens 55-71 8393269-4 1993 The percentage of carboxylated osteocalcin (HBC) was related to the plasma concentration of phylloquinone in patients with the apolipoprotein E genotype E3/3 (r = 0.52, P < 0.05), and in patients with the genotypes E2/3 and E2/2 (r = 0.23, P < 0.1). Vitamin K 1 92-105 bone gamma-carboxyglutamate protein Homo sapiens 31-42 8393269-4 1993 The percentage of carboxylated osteocalcin (HBC) was related to the plasma concentration of phylloquinone in patients with the apolipoprotein E genotype E3/3 (r = 0.52, P < 0.05), and in patients with the genotypes E2/3 and E2/2 (r = 0.23, P < 0.1). Vitamin K 1 92-105 keratin 88, pseudogene Homo sapiens 44-47 8393269-4 1993 The percentage of carboxylated osteocalcin (HBC) was related to the plasma concentration of phylloquinone in patients with the apolipoprotein E genotype E3/3 (r = 0.52, P < 0.05), and in patients with the genotypes E2/3 and E2/2 (r = 0.23, P < 0.1). Vitamin K 1 92-105 apolipoprotein E Homo sapiens 127-143 8393269-7 1993 Delivery to osteocalcin-producing osteoblasts seemed impaired in patients with the low receptor-affinity apolipoprotein variant E2, suggesting a major role of receptor-mediated chylomicron-remnant uptake in the transport of phylloquinone to bone. Vitamin K 1 224-237 bone gamma-carboxyglutamate protein Homo sapiens 12-23 1336373-6 1992 The results obtained strongly suggest that VDR in vitro can undergo gamma-carboxylation in the presence of vitamin K1 and that 15-25% of Glu residues in the VDR are carboxylated in vivo. Vitamin K 1 107-117 vitamin D receptor Rattus norvegicus 43-46 1325077-2 1992 With 3 and 6 h of 10 micrograms vitamin K1 treatment secreted prothrombin antigen levels, relative to total secreted protein levels, were increased 1.5-fold and 2.1-fold, respectively, over ethanol-treated control levels as determined by an enzyme-linked immunosorbent assay. Vitamin K 1 32-42 coagulation factor II, thrombin Homo sapiens 62-73 1325077-3 1992 Dose-response analysis with 3 h of 25 micrograms/ml vitamin K1 treatment demonstrated a maximal increase of 2.0-fold in secreted prothrombin antigen levels, relative to total secreted protein levels, over ethanol-treated control levels. Vitamin K 1 52-62 coagulation factor II, thrombin Homo sapiens 129-140 1325077-4 1992 Pulse-chase analysis with 35S-methionine and immunoprecipitation of 35S-labelled prothrombin demonstrated that, with vitamin K1 treatment (25 micrograms/ml, 3 h), the rate of prothrombin secretion increased approximately 2-fold and the total amount (intra- and extracellular) of prothrombin synthesized increased approximately 50% over ethanol-treated control levels. Vitamin K 1 117-127 coagulation factor II, thrombin Homo sapiens 81-92 1325077-4 1992 Pulse-chase analysis with 35S-methionine and immunoprecipitation of 35S-labelled prothrombin demonstrated that, with vitamin K1 treatment (25 micrograms/ml, 3 h), the rate of prothrombin secretion increased approximately 2-fold and the total amount (intra- and extracellular) of prothrombin synthesized increased approximately 50% over ethanol-treated control levels. Vitamin K 1 117-127 coagulation factor II, thrombin Homo sapiens 175-186 1325077-4 1992 Pulse-chase analysis with 35S-methionine and immunoprecipitation of 35S-labelled prothrombin demonstrated that, with vitamin K1 treatment (25 micrograms/ml, 3 h), the rate of prothrombin secretion increased approximately 2-fold and the total amount (intra- and extracellular) of prothrombin synthesized increased approximately 50% over ethanol-treated control levels. Vitamin K 1 117-127 coagulation factor II, thrombin Homo sapiens 175-186 1573142-0 1992 Development of a diet low in vitamin K-1 (phylloquinone). Vitamin K 1 42-55 keratin 1 Homo sapiens 37-40 1422449-1 1992 In rabbits with experimental hypocoagulation induced by phenylin, the use of a new dosage form of vitamin K1 for intravenous injections in does of 1 and 5 mg/kg led, in contrast to vicasol in a dose of 0.4 mg/kg, to an increase of the prothrombin index after 2 hours and to its complete normalization after 4 hours. Vitamin K 1 98-108 prothrombin Oryctolagus cuniculus 235-246 20368375-9 2009 HDL and C-reactive protein (CRP) levels improved gradually with increasing dietary phylloquinone intake (p < 0.05 for trend). Vitamin K 1 83-96 C-reactive protein Homo sapiens 8-26 1321512-0 1992 Non-specific effects of aquaMEPHYTON (vitamin K1) on prothrombin expression in human hepatoblastoma (HepG2) cells. Vitamin K 1 38-48 coagulation factor II, thrombin Homo sapiens 53-64 1321512-7 1992 The increases in secreted prothrombin antigen levels most likely result from non-specific effects of vitamin K1 or agents used to emulsify vitamin K1 on protein release from HepG2 cells. Vitamin K 1 101-111 coagulation factor II, thrombin Homo sapiens 26-37 1321512-7 1992 The increases in secreted prothrombin antigen levels most likely result from non-specific effects of vitamin K1 or agents used to emulsify vitamin K1 on protein release from HepG2 cells. Vitamin K 1 139-149 coagulation factor II, thrombin Homo sapiens 26-37 20368375-9 2009 HDL and C-reactive protein (CRP) levels improved gradually with increasing dietary phylloquinone intake (p < 0.05 for trend). Vitamin K 1 83-96 C-reactive protein Homo sapiens 28-31 34776998-8 2021 Finally, we carried out ligand docking studies and reported that PBP1 and GOBP2 have the capacity of binding vitamin K1 and multiple different vitamins. Vitamin K 1 109-119 general odorant-binding protein 2 Bombyx mori 74-79 23956412-3 2013 However, ICS1 also takes part in the synthesis of phylloquinone, which is incorporated into photosystem I and is an important component of photosynthetic electron transport in plants. Vitamin K 1 50-63 ADC synthase superfamily protein Arabidopsis thaliana 9-13 23956412-8 2013 However, ics1 plants treated with a phylloquinone precursor displayed symptoms of phenotypic reversion towards the wild type. Vitamin K 1 36-49 ADC synthase superfamily protein Arabidopsis thaliana 9-13 34836355-3 2021 The aim of this prospective screening study: ClinicalTrials.gov; Identifier: NTC3782025, was to evaluate the effects of intravenously administered vitamin K1 on Gas6 and its soluble (s)Axl receptor plasma levels in intensive care patients. Vitamin K 1 147-157 growth arrest specific 6 Homo sapiens 161-165 2720986-1 1989 By optimizing the conditions for determining trans-phylloquinone and its metabolite, K-2,3-epoxide, in serum through a two-step HPLC process combined with fluorometric detection after coulometric reduction, we have been able to develop a method applicable to small volumes of serum (200 to 500 microL). Vitamin K 1 45-64 RBPJ pseudogene 3 Homo sapiens 85-88 34444740-9 2021 In conclusion, the results suggest that vitamin K1 strengthens coagulation as measured by PT decrease and increases in the activity of vitamin K-dependent clotting factors and thrombin generation. Vitamin K 1 40-50 coagulation factor II, thrombin Homo sapiens 176-184 33684212-5 2021 Phylloquinone and menaquinones are capable of carboxylating MGP and other vitamin K-dependent proteins. Vitamin K 1 0-13 matrix Gla protein Homo sapiens 60-63 34069974-5 2021 We demonstrated that menaquinone 4 (MK-4), along with other vitamin Ks, including vitamin K1, has the potential to induce MDR1 and CYP3A4 gene expression. Vitamin K 1 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 34069974-5 2021 We demonstrated that menaquinone 4 (MK-4), along with other vitamin Ks, including vitamin K1, has the potential to induce MDR1 and CYP3A4 gene expression. Vitamin K 1 82-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 131-137 3259010-3 1988 However, GLA excretion was significantly higher with Ossopan or after pretreatment with vitamin K1. Vitamin K 1 88-98 galactosidase alpha Homo sapiens 9-12 3878250-10 1985 A positive correlation exists between plasma vitamin K1 and BGP for patient group A alone, but not for group B alone. Vitamin K 1 45-55 bone gamma-carboxyglutamate protein Homo sapiens 60-63 3428478-0 1987 Rat and human liver vitamin K epoxide reductase: inhibition by thiol blockers and vitamin K1. Vitamin K 1 82-92 vitamin K epoxide reductase complex subunit 1 Homo sapiens 20-47 3096849-1 1986 DT-diaphorase (DTD) is a flavoprotein that catalyses the two-electron reduction of various redox dyes and quinones such as menadione and phylloquinone. Vitamin K 1 137-150 NAD(P)H quinone dehydrogenase 1 Rattus norvegicus 0-13 4084561-3 1985 Reduction of vitamin K 2,3-epoxide occurred in a tightly coupled, two-step reaction initially to vitamin K and subsequently to vitamin K hydroquinone (vitamin KH2). Vitamin K 1 13-22 potassium voltage-gated channel modifier subfamily G member 1 Rattus norvegicus 159-162 3932474-8 1985 Human vitamin K epoxide reductase, which constitutes the other pathway for vitamin K1 reduction, has kinetic and enzymological characteristics that are very similar to the rat enzyme. Vitamin K 1 75-85 vitamin K epoxide reductase complex subunit 1 Homo sapiens 6-33